Key Points
- Director Barry Quart sold 20,129 shares on December 15 at an average price of $41.51 for a total of $835,554.79, cutting his stake by 61.60% to 12,546 shares; the sale was disclosed in an SEC Form 4.
- Kiniksa shares opened at $41.65 and trade near their 50-day ($40.03) and 200-day ($34.79) averages, with a market cap of $3.16B and a PE of 92.52; the company reported revenue of $180.9M (up 61.2% year-over-year) but missed quarterly EPS estimates.
- Analyst sentiment is broadly positive with six Buy and two Hold ratings, a consensus price target of $52 and an overall rating of Moderate Buy, while institutional investors own about 53.95% of the stock.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,048 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Eben Tessari also recently made the following trade(s):
- On Wednesday, November 26th, Eben Tessari sold 200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $42.89, for a total value of $8,578.00.
- On Monday, November 17th, Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.24, for a total value of $514,262.80.
- On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $37.67, for a total value of $465,902.56.
- On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $38.33, for a total value of $1,609,860.00.
Kiniksa Pharmaceuticals International Price Performance
NASDAQ KNSA traded down $0.06 on Thursday, reaching $41.41. 14,120 shares of the company's stock traded hands, compared to its average volume of 597,970. The stock has a market cap of $3.14 billion, a PE ratio of 92.02 and a beta of 0.02. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $42.98. The stock has a 50-day simple moving average of $40.03 and a 200 day simple moving average of $34.79.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. The company's revenue was up 61.2% compared to the same quarter last year. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have issued reports on KNSA. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a "buy" rating and a $60.00 price target for the company. Wedbush reissued an "outperform" rating and issued a $48.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday, October 17th. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, November 2nd. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $52.00.
Check Out Our Latest Research Report on KNSA
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
A number of institutional investors have recently bought and sold shares of KNSA. US Bancorp DE bought a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $33,000. Vanguard Group Inc. grew its position in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after buying an additional 151,604 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Kiniksa Pharmaceuticals International by 34.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 164,372 shares of the company's stock worth $3,651,000 after acquiring an additional 42,353 shares in the last quarter. Invesco Ltd. lifted its position in Kiniksa Pharmaceuticals International by 137.4% during the 1st quarter. Invesco Ltd. now owns 33,492 shares of the company's stock valued at $744,000 after acquiring an additional 19,384 shares during the period. Finally, Nuveen LLC bought a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $16,992,000. 53.95% of the stock is owned by institutional investors.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
